Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). WAVE Life Sciences's share price for the quarter that ended in Dec. 2024 was €12.2. WAVE Life Sciences's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 153.0 Mil. Therefore, WAVE Life Sciences's market cap for the quarter that ended in Dec. 2024 was €1,867.1 Mil.
WAVE Life Sciences's quarterly market cap
increased
from Jun. 2024 (€556.1 Mil) to Sep. 2024 (€1,083.3 Mil) and
increased
from Sep. 2024 (€1,083.3 Mil) to Dec. 2024 (€1,867.1 Mil).
WAVE Life Sciences's annual market cap
declined
from Dec. 2022 (€546.2 Mil) to Dec. 2023 (€538.6 Mil) but then
increased
from Dec. 2023 (€538.6 Mil) to Dec. 2024 (€1,867.1 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. WAVE Life Sciences's Enterprise Value for Today is €890.2 Mil.
WAVE Life Sciences Market Cap Historical Data
The historical data trend for WAVE Life Sciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of WAVE Life Sciences's Market Cap
For the Biotechnology subindustry, WAVE Life Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WAVE Life Sciences's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where WAVE Life Sciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
WAVE Life Sciences's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAVE Life Sciences (STU:1U5) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
WAVE Life Sciences Market Cap Related Terms
Thank you for viewing the detailed overview of WAVE Life Sciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:1U5 has been successfully added to your 